Introduction

PMMA injection risks deserve special attention because polymethyl methacrylate is a permanent filler: once injected, its microspheres do not naturally dissolve. Although one tightly regulated PMMA product has limited US approval for specific facial indications, that approval does not make every PMMA product, body area, dose, or injection technique safe. Moreover, complications may appear immediately or many years later, and complete removal can prove difficult or impossible. This evidence-based guide explains what PMMA is, which risks the data support, how regulators limit its use, and which alternatives may offer a better risk-benefit balance.

Medical disclaimer: This article provides general education, not diagnosis or individualized medical advice. Anyone with severe pain, vision changes, weakness, trouble speaking, shortness of breath, fever, rapidly increasing swelling, or white, gray, blue, or mottled skin after a filler injection should seek emergency medical care now.

PMMA Injection Risks: The Short Answer

PMMA can create durable volume, but permanence changes the safety equation. In particular, the body may form chronic inflammation, nodules, fibrosis, or foreign-body granulomas around microspheres that remain in tissue. Moreover, accidental injection into a blood vessel can block circulation and cause skin necrosis, blindness, or stroke, just as it can with other fillers. However, PMMA lacks a drug that reliably dissolves it after injection.

The US Food and Drug Administration emphasizes that permanent fillers can be difficult or impossible to remove. Furthermore, the agency has not approved any injectable filler for large-scale body contouring, including breast, buttock, or foot augmentation. Therefore, a product’s approval for one narrow facial purpose should never be interpreted as permission to use large volumes anywhere in the body.

Question	Evidence-based answer
Is PMMA a permanent filler?	Yes. The carrier gel changes after injection, but the PMMA microspheres remain.
Is PMMA FDA approved?	One product, Bellafill, has limited approval for nasolabial folds and certain cheek acne scars in adults over 21. Approval does not extend to the nose, lips, buttocks, genitals, or general body contouring.
Can PMMA be dissolved?	No approved or predictable injectable antidote dissolves PMMA microspheres.
Are all PMMA complications immediate?	No. Reports describe delayed nodules, granulomas, inflammation, migration, hypercalcemia, and kidney injury months or years later.
Does every PMMA injection cause a complication?	No. Nevertheless, published rates vary widely because product, dose, site, technique, follow-up, and study design differ.
Is hyaluronic acid risk-free?	No. However, it is temporary and clinicians can often use hyaluronidase off-label to reduce or remove it, which can make some complications more manageable.
What is the safest option for large-volume body or penile enhancement?	No injectable filler has FDA approval for those purposes. A qualified specialist should discuss nonfiller options, observation, or carefully selected surgery rather than improvised injections.

What Is PMMA Filler?

Understanding PMMA injection risks starts with the material itself. Polymethyl methacrylate, or PMMA, is a synthetic acrylic polymer. Medicine also uses specially manufactured PMMA in bone cement, dental materials, and certain implants. However, those devices are not interchangeable with injectable cosmetic fillers, and neither is industrial PMMA.

The FDA-approved US filler Bellafill combines nonresorbable PMMA microspheres with purified bovine collagen gel and lidocaine. According to the FDA-approved patient labeling, the collagen provides immediate volume while the microspheres act as a scaffold for the patient’s own collagen. Consequently, the visible result can persist after the carrier collagen diminishes.

PMMA is not the same as liquid acrylic or silicone

Confusing material names can hide major safety differences. For example, methyl methacrylate, or MMA, is the liquid monomer used to manufacture solid PMMA, whereas medical PMMA microspheres are finished polymer particles. Similarly, liquid silicone is a different permanent material with its own complications and regulatory history.

Material	What it is	Typical medical or cosmetic role	Key safety point
PMMA microspheres	Solid acrylic polymer particles	Permanent filler component and some medical devices	Particles persist and cannot be predictably dissolved after injection.
MMA monomer	Reactive liquid chemical used to make PMMA	Manufacturing component	It is not an injectable cosmetic filler.
Liquid silicone	Permanent silicone oil	Limited medical uses; sometimes injected illegally for contouring	It can migrate, inflame tissue, embolize, and prove extremely difficult to remove.
Hyaluronic acid, or HA	Sugar-based gel related to a natural body molecule	Temporary facial filler	It can still occlude vessels, although hyaluronidase may help dissolve the gel.

Why microsphere quality and injection context matter

Particle size, surface smoothness, sterility, carrier composition, injection depth, product concentration, and volume can influence tissue response. Therefore, evidence about an FDA-approved, standardized implant cannot validate an unknown bulk product or compounded material. In practice, counterfeit products and injections outside regulated medical settings add risks that clinical trials cannot measure.

Product quality also cannot neutralize a dangerous indication. Even a genuine filler can cause harm when someone injects it into an artery, uses excessive volume, places it in a high-risk anatomical plane, or treats an unsuitable patient. Thus, questions about PMMA safety must always include the product, purpose, site, volume, injector, and rescue plan.

PMMA Injection Risks and FDA Approval

Regulatory status provides essential context for PMMA injection risks. Yes, the FDA has approved PMMA filler, but only in a narrow sense. The agency approved Bellafill as a permanent dermal filler for correcting nasolabial folds and for moderate to severe, atrophic, distensible acne scars on the cheek in adults older than 21. Its official FDA premarket approval record defines those indications.

By contrast, FDA approval does not cover PMMA injection into the lips, nose, glabella, forehead, eyelids, breasts, buttocks, calves, feet, penis, or scrotum. The agency also advises against using any dermal filler for body contouring or injection into muscle, tendon, ligament, or bone. Accordingly, the phrase “FDA-approved material” does not mean “FDA-approved treatment” when the site or purpose differs from the label.

US restrictions and product-specific precautions

Bellafill contains bovine collagen, so its labeling requires allergy screening and a skin test before treatment. In addition, the label lists contraindications that include a positive collagen skin test, severe allergies or anaphylaxis, bovine collagen or lidocaine allergy, bleeding disorders, lip augmentation, and susceptibility to keloid or hypertrophic scarring. The label also states that clinicians should not inject the product into blood vessels.

Dose context matters as well. The patient label says that safety beyond 3.5 mL per treatment site or 8.9 mL overall has not been established. Consequently, evidence from small facial injections cannot justify hundreds of milliliters for gluteal or body augmentation.

Brazil: approved indications are not unrestricted aesthetic permission

Brazilian regulation has generated confusing headlines. In July 2025, Anvisa maintained PMMA only for the indications already approved in Brazil and stressed that approved instructions do not authorize indiscriminate aesthetic use. More recently, in March 2026, the agency again recommended dermal fillers only within their approved indications.

The Brazilian Federal Council of Medicine asked Anvisa to prohibit aesthetic PMMA use in January 2025. However, that CFM request was a regulatory petition, not itself a national ban. Therefore, patients should check the current Anvisa registration, the exact package insert, and the professional’s legal scope instead of relying on a viral headline.

Claim	Accurate interpretation
“PMMA is FDA approved.”	One specific PMMA-containing product has approval for two specific facial indications in adults over 21.
“The material is approved, so any use is approved.”	False. Approval attaches to the exact product, indication, site, population, labeling, and manufacturing controls.
“Brazil banned all PMMA.”	Not as of the cited 2025 Anvisa decision. Anvisa maintained existing approved indications and rejected indiscriminate aesthetic use.
“A doctor can safely use any volume off-label.”	False. Professional licensure cannot erase dose, anatomy, product, or evidence limitations.
“Off-label always means illegal or negligent.”	Not necessarily. However, off-label care requires a defensible clinical rationale, informed consent, competence, and appropriate safeguards.

Why Permanence Increases PMMA Injection Risks

Permanence amplifies several PMMA injection risks. Temporary fillers gradually break down, while PMMA microspheres remain as foreign material. Therefore, a good early result does not eliminate the possibility of later inflammation or aesthetic mismatch. Facial fat, skin, bone, and muscle continue to age, yet the implant does not age in the same way.

Moreover, permanence limits corrective options. A clinician can sometimes excise a localized PMMA deposit, but injected microspheres may disperse between normal tissue planes. As a result, complete removal can require sacrificing healthy skin, fat, muscle, vessels, or nerves, and even aggressive surgery may leave material behind.

A permanent result is not the same as a stable result

PMMA advocates often describe the material as stable because it does not biodegrade. Nevertheless, the surrounding tissue remains biologically active. Infection, trauma, immune activation, tissue aging, or another procedure may change the local environment, and the body can maintain a chronic foreign-body response.

In addition, injected volume can shift the mechanical balance of mobile areas. The lips, eyelids, penis, and buttocks move, stretch, and experience pressure. Consequently, lumps, asymmetry, fibrosis, or functional limitation can become more noticeable over time even when the polymer itself stays chemically stable.

The Main PMMA Injection Risks

The main PMMA injection risks range from mild, short-lived swelling to irreversible loss of tissue or vision. Severity also depends on timing: an early vascular emergency demands immediate action, whereas a late granuloma may require months of diagnostic and therapeutic work.

A 2025 narrative review included 27 studies and cataloged early pain, redness, edema, bruising, allergy, nodules, and necrosis. In addition, it described delayed chronic inflammation, granulomas, ulceration, migration, infection, hypercalcemia, and renal failure. However, the review of PMMA complications in aesthetic procedures combined heterogeneous reports and cannot calculate a universal incidence.

Pain, redness, swelling, bruising, and itching

Needle trauma and tissue expansion commonly cause short-term pain, erythema, edema, bruising, tenderness, or itching after many fillers. For example, the Bellafill acne-scar study diary recorded high rates of brief local reactions, although most were mild and resolved in about a week. These expected reactions still need monitoring because worsening pain, spreading redness, fever, drainage, or color change can signal infection or ischemia rather than routine recovery.

Persistent edema creates a different problem. Because PMMA remains in tissue, chronic inflammation or lymphatic obstruction may maintain swelling long after the injection. Therefore, clinicians should investigate recurrent or one-sided edema instead of repeatedly treating it as a simple allergy without confirming the cause.

Vascular occlusion, skin necrosis, blindness, and stroke

The most time-critical complication occurs when filler enters or compresses a blood vessel. Blood flow can stop downstream, depriving skin or the eye of oxygen. Consequently, a patient may develop severe pain, blanching, a dusky or net-like skin pattern, tissue death, visual loss, or neurologic deficits.

All injectable fillers can cause vascular occlusion. However, a permanent particulate filler creates an additional obstacle because clinicians cannot dissolve it with hyaluronidase. The FDA dermal filler safety page warns that accidental intravascular injection can cause necrosis, blindness, or stroke, and the Bellafill label documents a postmarket report of irreversible blindness after an off-label canthal or periorbital injection.

An anatomical “danger zone” is not a promise that other sites are safe. Nevertheless, the nose, glabella, forehead, and periorbital region have vascular connections to the eye and brain, so injections there carry especially grave consequences. Therefore, patients should reject anyone who presents a high-risk area as routine or guarantees that a cannula makes blindness impossible.

Nodules, lumps, fibrosis, and foreign-body granulomas

A nodule is a palpable lump; a granuloma is a specific immune response that requires clinical or histologic evaluation. Although people often use the terms interchangeably, not every lump represents a granuloma. Poor placement, superficial product, aggregation, infection, scar formation, or delayed inflammation can also create nodules.

Granulomas form when immune cells surround material that they cannot eliminate. In a 2020 systematic review of 1,842 facial patients, researchers reported a 4.9% overall complication frequency and a 1.9% granuloma frequency, with reported onset ranging from 6 to 180 months. However, the review indexed in PubMed pooled heterogeneous, mostly low-level studies and did not cover high-volume body injections.

Another selected cohort illustrates how late problems can appear. Among 209 people who already presented with facial PMMA complications, the median time to presentation was 71 months, and one case appeared 330 months, or 27.5 years, after injection. Because the 209-case analysis included only patients with complications, its 64.6% granuloma proportion cannot estimate the risk among all injected patients. Still, the long latency challenges the idea that several uneventful years equal lifetime safety.

Infection, abscess, drainage, and possible biofilm

Any injection can carry skin bacteria into deeper tissue. Moreover, permanent foreign material can provide a surface around which microorganisms persist. Acute infection may cause warmth, pain, redness, fever, pus, or abscess, while indolent infection may resemble an inflammatory nodule.

Treatment requires diagnosis because steroids can worsen an untreated infection, whereas antibiotics alone cannot correct every sterile granuloma or mechanical lump. Therefore, clinicians may use cultures, imaging, biopsy, and multidisciplinary assessment before choosing therapy. Patients should never squeeze, puncture, massage aggressively, or inject unprescribed substances into a suspected PMMA complication.

Migration, contour irregularity, and disfigurement

Injected particles can spread beyond the intended pocket during placement, through pressure, or along tissue planes. In addition, uneven distribution may cause visible ridges, firmness, asymmetry, or overcorrection. These changes can become more obvious as swelling resolves or normal tissue ages.

Permanent overfilling also removes the option of simply waiting for the product to metabolize. Consequently, correction may involve camouflage with another material, staged surgery, or acceptance of some residual irregularity. Adding more filler without a clear diagnosis can compound the problem.

Hypercalcemia and kidney injury

Systemic complications are uncommon in the literature, but they can be severe. Chronic granulomatous inflammation may activate vitamin D outside the kidneys, increase intestinal calcium absorption, and raise blood calcium. As a result, patients can develop thirst, frequent urination, constipation, nausea, weakness, confusion, kidney stones, or renal failure.

A systematic review of cosmetic injection-related hypercalcemia found 23 published patients across several permanent materials; seven had received PMMA. The mean reported latency was about eight years, although cases ranged from months to 28 years. Importantly, the European Journal of Endocrinology review found renal failure in 82% of the overall reported group and two deaths, but it did not provide PMMA-specific outcome rates. Therefore, those severe proportions describe a highly selected collection of case reports, not the incidence among everyone who receives PMMA.

Brazilian nephrologists have also described severe hypercalcemia and chronic kidney disease after high-volume PMMA injections. In their two-patient case report, granulomatous tissue appeared to produce excess active vitamin D. Although two cases cannot quantify risk, they show why clinicians should ask about remote cosmetic injections when investigating unexplained hypercalcemia or kidney disease.

Allergy and hypersensitivity

PMMA itself differs from the bovine collagen carrier in Bellafill. Because bovine collagen can trigger hypersensitivity, the approved label requires a skin test and excludes patients with a positive response or relevant allergy. Even after a negative test, patients still need to report systemic symptoms or persistent local inflammation.

Other PMMA formulations may use different carriers or additives. Therefore, a patient must know the exact brand, lot, and ingredient list. Vague descriptions such as “bioplasty,” “acrylic gel,” or “permanent collagen stimulator” do not provide enough information for informed consent.

Functional injury and psychological burden

Complications do not end with appearance. Fibrosis near the mouth can restrict movement, periocular inflammation can affect eyelid closure, and penile scarring can impair sexual function. Similarly, buttock complications may interfere with sitting, exercise, or sleep.

Repeated procedures, uncertain diagnosis, visible deformity, and the fear of future inflammation can also cause substantial emotional distress. Consequently, good care may require reconstructive surgery, dermatology, infectious disease, nephrology, ophthalmology, urology, pain management, and mental health support rather than a single cosmetic revision.

What Studies Show About PMMA Injection Risks

No single percentage captures PMMA injection risks. Clinical trials tend to use standardized product, small facial volumes, trained injectors, and defined follow-up. By contrast, complication series often collect severe referrals after unknown products, large doses, or off-label injections. Both types of evidence answer useful but different questions.

FDA-label data from controlled facial use

The Bellafill patient label reports local adverse events from studies of approved facial indications. These figures apply to that product and study context, not to all PMMA injections.

Study or dataset	Population	Finding	How to interpret it
Nasolabial-fold studies	391 Bellafill-treated patients	Lumpiness: 13 patients, 3.3%	Product- and indication-specific; mostly mild or moderate events in studied facial use.
Nasolabial-fold studies	391 patients	Persistent swelling or redness: 13, 3.3%	“Persistent” in the label does not represent every delayed event over a lifetime.
Nasolabial-fold studies	391 patients	Increased sensitivity: 7, 1.8%	Small facial volumes cannot model high-volume body augmentation.
Nasolabial-fold studies	391 patients	Rash or itching lasting over 48 hours: 5, 1.3%	Bellafill’s bovine collagen carrier requires allergy screening.
Acne-scar diary	Bellafill study participants	Swelling 69.2%, redness 66.2%, pain 63.8%, bruising 59.2%, lumps 57.7%	Most diary reactions were mild and resolved in roughly one week; these are not equivalent to permanent complications.
Acne-scar effectiveness	87 evaluable Bellafill patients vs 46 saline controls	Response at six months: 64% vs 33%	The trial shows benefit for selected distensible cheek scars, not general cosmetic safety.

Source: FDA-approved Bellafill patient labeling.

Reviews and complication reports

The table below separates denominator-based cohorts from reports that only count people who already developed problems. This distinction prevents a common error: dividing published complications by an unknown number of procedures and calling the result an incidence rate.

Evidence source	Scope	Selected finding	Main limitation
2020 systematic review	1,842 facial patients	4.9% general complication frequency; 1.9% granuloma frequency; granulomas reported 6 to 180 months later	Heterogeneous, mostly lower-level studies; facial use only; variable follow-up and definitions.
2024 integrative review	38 descriptive publications and 587 reported complication cases	Volumes ranged from 1.9 to 900 mL; 64% of cases came from Brazil	No denominator of all procedures; case reports and referral bias prevent incidence estimates.
209-case facial complication cohort	209 patients who already had a complication	Median presentation at 71 months; latest at 330 months; granulomas in 135 cases	Complication-selected cohort; proportions cannot predict an injected patient’s absolute risk.
ECRI evidence review for FDA	37 included PMMA publications across medical uses	Moderate evidence linked dermal filler use to long-term local inflammation; evidence for systemic hypercalcemia was very low	Mixed study designs and applications; rarity and reporting bias limit certainty.
Hypercalcemia systematic review	23 published cases involving several injected permanent materials	Seven PMMA patients; overall renal failure in 82%; mean latency about eight years	Case-report collection with severe selection bias; outcomes not separated by material.
Rabbit-ear embolism experiment	60 rabbit ears exposed to PMMA or HA	In that model, HA caused more seven-day necrosis than PMMA at matched volumes	Animal arteries, short follow-up, no delayed PMMA outcomes, and industry product support; not a human safety comparison.

The 2024 review, available through the Brazilian Journal of Plastic Surgery, found granulomas, nodules, inflammation, infection, necrosis, hypercalcemia, and renal problems across published reports. However, the authors counted complication cases, not all treated patients. Therefore, the paper maps the range and context of harm but cannot tell a new patient, for example, that the risk equals 1 in 587.

Why apparently conflicting studies may both be true

A controlled facial study can show acceptable short-term performance while referral centers still treat devastating late cases. First, clinical trials select patients and products. Second, cosmetic markets introduce different injectors, volumes, sites, and unregistered materials. Finally, rare events may not appear until thousands of procedures or many years of follow-up have accumulated.

The same logic applies to the 2019 rabbit-ear study supplied with this article. At 0.1 mL, investigators observed mild necrosis in 5% of PMMA-treated ears versus 60% of HA-treated ears; at 0.2 mL, the proportions were 30% and 100%, respectively. Nevertheless, the peer-reviewed animal paper followed animals for only seven days and did not model chronic granulomas, removal difficulty, human facial anatomy, or clinical rescue with hyaluronidase. Moreover, the authors reported that a PMMA product supplier funded the work and supplied materials. Thus, the experiment asks how two gels behaved after deliberate arterial embolization in rabbit ears, not whether PMMA is safer for people over decades.

Evidence certainty at a glance

Question	Confidence	Best current conclusion
Can PMMA cause local nodules, granulomas, and chronic inflammation?	Moderate	Yes. Multiple cohorts, reviews, labels, and histologic reports support this association.
Can filler vascular occlusion cause necrosis, blindness, or stroke?	High for fillers as a class	Yes. The complication is rare but medically urgent; material and anatomy affect management.
Can PMMA-related granulomas contribute to hypercalcemia and kidney injury?	Low to very low for frequency, credible for mechanism	Yes, published cases support the mechanism, but available evidence cannot estimate absolute risk.
Is high-volume gluteal PMMA safe?	Very low evidence of safety	No credible trial establishes safety, while severe complication reports and regulatory restrictions create substantial concern.
Is PMMA safer than HA overall?	Insufficient for a universal ranking	No. Safety depends on indication and endpoint; PMMA is permanent, while HA is temporary and often more reversible.
Can clinicians completely remove injected PMMA?	Low certainty for any individual, strong practical concern	Sometimes they can debulk a localized deposit, but diffuse complete removal may be impossible or disfiguring.

PMMA Injection Risks by Body Area and Volume

Anatomy changes PMMA injection risks. A tiny volume near the eye may threaten vision, whereas a large gluteal dose increases total foreign-body burden and exposes broad tissue planes. Therefore, “How much?” and “Where?” matter as much as “Which filler?”

Nasolabial folds and selected cheek acne scars

These are the only FDA-approved Bellafill indications. Even here, treatment requires an appropriately trained licensed clinician, genuine product, allergy testing, sterile technique, conservative volume, and informed consent. In addition, PMMA injection risks remain relevant because approval reduces uncertainty but does not eliminate complications.

Distensible acne scars also differ from ice-pick scars, active acne, infection, and generalized texture changes. Consequently, an acne-scar specialist may recommend subcision, laser, microneedling, chemical reconstruction, temporary filler, or a combination rather than permanent filler alone.

Nose, glabella, forehead, and around the eyes

PMMA injection risks become especially consequential in these high-risk facial sites. These areas connect through vessels that can carry filler toward the ophthalmic circulation. As a result, an error can cause blindness or stroke within minutes. The FDA recommends against filler injection in the nose, glabella, forehead, and periorbital region, and Bellafill’s labeling does not approve those sites.

PMMA also creates a permanent contour in areas with thin skin and little room for error. Therefore, visible beads, lumps, compression, and surgical removal can become especially difficult. A noninvasive approach or specialist-led surgical plan may offer a more rational risk-benefit profile.

Lips

In the lips, PMMA injection risks include permanent lumps, stiffness, asymmetry, and vascular injury. The lips move constantly, swell readily, and contain dense vascular networks. Bellafill labeling specifically contraindicates lip augmentation. Moreover, permanent complications can affect speech, eating, kissing, and expression.

Temporary HA products have approved lip indications in the United States, depending on brand and age group. However, lip HA still carries risks such as swelling, nodules, infection, asymmetry, and vascular occlusion. The safer comparison concerns reversibility and regulatory evidence, not an absence of complications.

Buttocks and large-volume body contouring

Gluteal PMMA injection risks grow more concerning as permanent volume and tissue exposure increase. Meanwhile, the FDA has approved no injectable filler for enlarging or contouring the buttocks, breasts, or other large body areas. Its consumer guidance warns that large-scale filler injection can cause long-term pain, infection, scarring, disfigurement, and death. Consequently, hundreds of milliliters of PMMA cannot borrow a safety claim from trials that used small facial volumes.

The 587-case integrative review found reported volumes as high as 900 mL and identified the gluteal region among the most frequently described complication sites. Nevertheless, it lacked a procedure denominator, so it cannot calculate a dose-specific incidence. The responsible conclusion is narrower but still important: high-volume use falls far outside FDA-approved facial evidence, increases permanent material burden, and has produced severe published cases.

Autologous fat transfer is not automatically safe either. A Brazilian butt lift can cause fatal fat embolism when fat enters deep vessels. Therefore, anyone considering gluteal surgery should consult a board-certified plastic surgeon who follows current safety guidance, including the joint gluteal fat grafting safety statement.

Penis and scrotum

Penile PMMA injection risks include both cosmetic and functional harm. No dermal filler has FDA approval for penile or scrotal enlargement. The penis combines thin mobile tissue, important vessels, nerves, lymphatics, erectile structures, and high functional stakes. Consequently, infection, necrosis, migration, fibrosis, deformity, pain, and sexual dysfunction can carry consequences far beyond cosmetic dissatisfaction.

PMMA remains permanent if expectations change or the tissue reacts. In addition, removal may require circumferential dissection, skin excision, grafts, or staged reconstruction. Patients should regard claims of a quick, permanent, nonsurgical enlargement as a reason for deeper scrutiny, not as proof of convenience.

PMMA Injection Risks in Penis Fillers

Current evidence cannot establish that PMMA penile filler offers an acceptable long-term risk-benefit balance. Indeed, PMMA injection risks in penile tissue remain difficult to quantify. The procedure represents an off-label, non-FDA-approved use, and the evidence base relies heavily on uncontrolled series, retrospective reports, and complication cases rather than randomized comparisons with long follow-up.

A 2016 single-practice report described 729 men and about 1,500 PMMA sessions. Yet only 203 participants returned questionnaires, approximately half perceived some irregularity, and three men underwent nodule removal. The study indexed in PubMed had no control group and limited ability to detect late complications or outcomes among nonresponders. Therefore, the often-quoted 0.4% surgical nodule figure should not be presented as a lifetime complication rate.

More recently, a 2025 emergency medicine case report described penile sepsis and an abscess-like collection ten days after PMMA injection abroad. A single case report cannot measure frequency, but it demonstrates a plausible severe acute outcome. Similarly, broader reviews of penile foreign-material injections document delayed inflammation, necrosis, deformity, and frequent surgical treatment, although many reported injections involved silicone or paraffin rather than PMMA.

How to interpret online penile filler case studies

The Rejuvall page supplied for this review describes a severe penile PMMA outcome. However, it is a clinic-authored, non-peer-reviewed case study, and parts of the history reportedly came from online patient material. Consequently, the Rejuvall case page can illustrate questions that deserve investigation, but it cannot establish causation, incidence, or comparative safety.

By contrast, a recent peer-reviewed clinical review concluded that HA generally produced lower complication rates than PMMA, silicone, or polylactic acid in standardized low-volume penile protocols. Still, the 2025 review in Translational Andrology and Urology does not convert penile HA into an FDA-approved or risk-free treatment. Thus, the most defensible next step is consultation with a qualified urologist or sexual-medicine specialist who does not profit from a predetermined injectable solution.

Safer Alternatives That Reduce Some PMMA Injection Risks

“Safer” always requires a defined goal, body site, patient, product, and comparator. For many facial indications, temporary FDA-approved fillers reduce some PMMA injection risks and offer a more forgiving starting point. By contrast, the safer alternative for large-volume body or genital enlargement may be no injectable filler at all.

Filler material comparison

Option	Typical duration or behavior	PMMA injection risks it may reduce	Important risks and limits	Reversal or removal
Hyaluronic acid, or HA	Often about 6 to 12 months, although product and site vary	Temporary; extensive facial experience; many FDA-approved products and indications	Swelling, infection, nodules, migration, vascular occlusion, necrosis, blindness, or stroke can still occur	Hyaluronidase can often reduce HA off-label, but results vary and no rescue guarantees restored vision.
Calcium hydroxylapatite, or CaHA	Often around 18 months	Biocompatible mineral-like particles; collagen stimulation; temporary to semipermanent effect	Nodules, vascular occlusion, visibility in some tissues, and technique-sensitive placement	No approved direct dissolving agent; removal can be difficult.
Poly-L-lactic acid, or PLLA	Gradual collagen stimulation; effects may last up to two years	No permanent acrylic microspheres; gradual result can suit diffuse volume loss	Requires a treatment series; delayed nodules and vascular complications remain possible	No direct dissolving agent.
Autologous fat transfer	Variable survival; some transferred fat may persist	Uses the patient’s own tissue and can treat larger volume deficits	Surgical risks, infection, asymmetry, fat necrosis, unpredictable resorption, and potentially fatal fat embolism in gluteal grafting	Surgical revision may help, but precise reversal is not available.
No filler or staged nonfiller treatment	No implanted filler	Avoids filler-specific vascular, foreign-body, and removal risks	May deliver subtler results or require several sessions	Usually no filler removal issue.
Surgery by a qualified specialist	Potentially long-lasting structural change	May address anatomy directly instead of dispersing injectable particles	Anesthesia, scars, infection, bleeding, nerve injury, thrombosis, and procedure-specific risks	Revision may be possible but not simple.

Duration estimates come from the FDA overview of approved dermal filler materials. Individual metabolism, product properties, dose, and injection site can shorten or extend results.

Hyaluronic acid: usually more reversible, never trivial

HA often represents the first injectable alternative to discuss for appropriate facial treatment. Because it is temporary, patients can reassess their preferences as facial anatomy and aesthetic goals change. Moreover, trained clinicians can use hyaluronidase off-label to dissolve many HA deposits or treat some vascular events.

Nevertheless, hyaluronidase is not a universal safety net. The FDA’s 2025 executive summary on dermal filler risks notes that no hyaluronidase product has specific approval for filler removal and that no reliable treatment reverses every filler-related blindness event. Therefore, product reversibility should supplement, not replace, anatomical expertise and emergency preparedness.

A large self-reported study of 370 US dermatologists covered about 1.7 million syringes of filler. Investigators estimated one vascular occlusion per 6,410 needle injections versus one per 40,882 cannula injections, while greater injector experience also correlated with lower odds. However, the JAMA Dermatology study pooled fillers and relied on retrospective clinician reports, so the figures should not become a PMMA-specific risk estimate or a guarantee for cannulas.

HA’s scale of use also provides more real-world exposure, although popularity never proves safety. The ISAPS Global Survey 2024 estimated about 6.3 million HA procedures by plastic surgeons worldwide, a 5.2% increase from 2023. By contrast, that survey does not make HA suitable for every site or show that its complication rate equals zero.

Calcium hydroxylapatite and poly-L-lactic acid

CaHA and PLLA avoid permanent acrylic beads, yet neither has a direct dissolving enzyme. The former supplies immediate structure and stimulates collagen, whereas PLLA gradually stimulates collagen across a treatment series. Consequently, clinicians choose them for different tissues and goals.

Both materials demand careful depth and technique. For example, superficial placement can make nodules or visibility more likely, while arterial injection can still cause catastrophic ischemia. Thus, “biostimulatory” does not mean natural, reversible, or free from vascular risk.

Autologous fat grafting

Fat transfer uses a patient’s harvested tissue and can address larger volume deficits than a syringe filler. However, it requires surgery, and some fat resorbs unpredictably. In addition, fat necrosis, oil cysts, contour irregularity, infection, and embolism can occur.

Gluteal fat grafting deserves special caution because professional societies have reported fatalities from pulmonary fat embolism. Accordingly, it may be a more evidence-based option than unapproved bulk PMMA in a carefully selected patient, but nobody should market it as inherently safe. Surgeon credentials, ultrasound-guided technique where required, facility standards, and postoperative care materially affect risk.

Nonfiller and no-treatment options

Some concerns respond better to skin care, energy-based devices, resurfacing, subcision, microneedling, laser treatment, chemical peels, scar surgery, psychotherapy for body-image distress, or simply observation. For instance, an atrophic acne scar may improve through release and remodeling rather than permanent filling. Similarly, a perceived penile-size problem may reflect normal anatomy, erectile function, weight distribution, or anxiety that an injection cannot solve.

No treatment has zero tradeoffs. Nevertheless, declining or delaying an elective permanent implant preserves future options. A cooling-off period also gives the patient time to compare specialists, confirm product registration, and separate personal goals from sales pressure.

Goal-based alternatives

Goal	Options to discuss first	Why they may offer a better starting point	Essential caveat
Nasolabial folds	Temporary HA, conservative CaHA, skin tightening, or surgery when indicated	Temporary or anatomically targeted choices allow reassessment	Every injectable can occlude a vessel.
Distensible cheek acne scars	Subcision, HA, Bellafill in eligible adults, resurfacing, microneedling, or combination therapy	Scar type can guide treatment instead of filling every depression	Active acne, keloid risk, skin type, and scar morphology change the plan.
Lip enhancement	FDA-approved HA product for the relevant age group or no treatment	Temporary products suit a mobile area and may be dissolvable	Swelling and vascular occlusion remain possible; permanent PMMA is contraindicated in Bellafill labeling.
Nose reshaping	Surgical rhinoplasty, camouflage makeup, or no treatment	Surgery can address structure under controlled visualization	Both surgery and nonsurgical nose filler carry meaningful risks; nasal filler can cause blindness.
Buttock enlargement	No procedure, exercise and clothing strategies, implants in selected patients, or specialist fat grafting	Avoids unapproved bulk filler and diffuse permanent particles	Surgery and fat transfer have serious risks and require expert selection.
Penile size concern	Urologic assessment, counseling, traction for selected indications, weight management, or no intervention	Addresses function, anatomy, and expectations without permanent foreign particles	Evidence varies by intervention; no penile filler has FDA approval.
HIV-associated lipoatrophy or reconstructive volume loss	Condition-specific consultation and products approved in the relevant country	Reconstructive goals and medical context require individualized evidence	Regulatory indications differ by country and product.

How to Reduce PMMA Injection Risks Before Treatment

Reducing PMMA injection risks begins before the needle enters the skin. First, define the exact problem and ask whether filler actually addresses it. Next, compare temporary, permanent, surgical, and no-treatment options. Finally, verify the professional, product, facility, and emergency plan independently.

Use a qualified, anatomy-trained medical professional

Choose a licensed clinician with formal training in the exact body area and procedure. In addition, verify board certification through the relevant national specialty board rather than trusting social-media titles. Experience should include complication recognition and management, not only attractive before-and-after photographs.

Ask who will inject, who will supervise, and who provides emergency coverage. Moreover, confirm that the procedure occurs in a legitimate clinical facility with sterile supplies and a written transfer pathway. A low price, hotel room, home visit, party setting, or cross-border package with no follow-up should trigger caution.

Verify the exact product and indication

Request the brand, manufacturer, regulatory registration, lot number, expiration date, and unopened package before treatment. Then compare the intended site with the official label. If a clinician proposes off-label use, ask what evidence supports it, what alternatives exist, and how the off-label status changes risk.

Never accept a transferred syringe, unlabeled jar, industrial material, or product purchased from an online marketplace. The FDA specifically warns consumers not to buy dermal fillers online or use needle-free injection devices. Therefore, “same ingredient” is not an adequate substitute for traceable medical manufacturing.

Demand a volume-specific plan

Ask for the expected volume per session, total planned volume, number of sessions, anatomical plane, and stopping criteria. Because complications may rise with product burden and technical error, vague promises of “as much as needed” are unsafe. A responsible clinician should explain why the proposed dose fits published and labeled experience.

Staged treatment can reduce overcorrection and allow tissue assessment. However, dividing a fundamentally unsupported high-volume plan into several sessions does not make the indication evidence-based. The cumulative permanent burden still matters.

Review medical history and interactions

Disclose allergies, prior filler brands and dates, autoimmune or inflammatory disease, infections, dental procedures, immune-modulating drugs, anticoagulants, bleeding disorders, pregnancy status, scar history, and previous surgery. Furthermore, tell the clinician about implants even if another provider placed them years ago.

Bellafill candidates need the required bovine collagen skin test and waiting period. Conversely, a negative test does not prevent vascular occlusion, infection, poor placement, or later foreign-body inflammation. Screening narrows one risk; it does not certify the entire procedure as safe.

Examine the emergency plan

Before an HA injection, confirm that the clinic stocks unexpired hyaluronidase and knows a vascular-occlusion protocol. For every filler, ask how the team handles sudden vision loss, neurologic symptoms, anaphylaxis, and transfer to an emergency department or ophthalmology service. PMMA requires particular caution because no enzyme dissolves it.

Do not accept “this has never happened to me” as an emergency strategy. Rare complications require preparation precisely because a clinician may encounter them infrequently. In addition, a provider who dismisses questions about blindness or necrosis may not offer balanced informed consent.

Keep permanent records

Photograph the box, label, lot number, and treatment map with permission. Also keep the consent form, invoice, provider contact details, injected volumes, and dates. Years later, those records can help radiologists, surgeons, dermatologists, nephrologists, and emergency clinicians interpret symptoms.

Tell future clinicians about permanent filler before dental work, facial surgery, imaging, or treatment of an unexplained inflammatory problem. Although PMMA may not cause the new symptom, knowing its location can prevent diagnostic confusion and inadvertent injection through affected tissue.

Warning Signs Related to PMMA Injection Risks

Some PMMA injection risks demand treatment within minutes. Therefore, do not wait for the injector to answer a direct message if blood flow, vision, breathing, or neurologic function may be threatened.

Seek emergency care immediately

• New vision loss, blurred vision, double vision, eye pain, drooping eyelid, or loss of part of the visual field
• Severe or escalating pain, especially pain out of proportion to expected tenderness
• Skin that becomes white, gray, blue, purple, cold, or mottled in a branching or net-like pattern
• Facial weakness, arm or leg weakness, trouble speaking, confusion, severe headache, or loss of balance
• Shortness of breath, chest pain, collapse, widespread hives, tongue swelling, or throat tightness
• Rapidly expanding swelling, high fever, fainting, or signs of sepsis

The FDA advises immediate medical attention for unusual pain, vision changes, skin color changes near the injection site, or stroke symptoms. Importantly, a patient should tell emergency staff the exact filler, site, time, volume, and injector when known.

Arrange urgent medical review

• Increasing redness, warmth, drainage, fever, or a painful soft mass
• An open wound, blister, ulcer, or darkening skin
• A new firm nodule with inflammation or tenderness
• Genital swelling, difficulty urinating, discharge, skin breakdown, or painful erection
• Persistent vomiting, marked thirst, frequent urination, confusion, profound weakness, or flank pain

These signs may reflect infection, tissue injury, obstruction, or metabolic disturbance. Consequently, same-day assessment may prevent progression, particularly when symptoms intensify rather than stabilize.

Discuss delayed symptoms with an experienced clinician

• New lumps, recurrent swelling, firmness, asymmetry, redness, or pain months or years later
• Skin thinning, yellow discoloration, migration, or contour change
• Reduced movement, eyelid malposition, oral restriction, or sexual dysfunction
• Recurrent kidney stones, unexplained high calcium, or worsening kidney function

Delayed symptoms do not prove that PMMA caused the problem. Nevertheless, the history should prompt targeted evaluation because a permanent implant remains relevant long after the original clinic visit.

Diagnosing and Treating PMMA Injection Risks

Managing PMMA injection risks requires an accurate diagnosis. Treatment depends on mechanism, material distribution, anatomy, infection status, timing, and severity. Therefore, no online protocol can safely replace examination and imaging.

Diagnosis starts with identifying the material

The clinician should reconstruct the product, dates, volumes, injection planes, previous treatments, and symptom timeline. If records are missing, high-frequency ultrasound can sometimes map filler deposits and guide procedures; MRI or CT may help in deeper or systemic disease. In addition, clinicians may order cultures, inflammatory markers, calcium, kidney tests, vitamin D metabolites, or biopsy when the differential diagnosis requires them.

Pathology can distinguish a foreign-body granuloma from some tumors, infections, and other inflammatory diseases. However, biopsy location and technique matter in cosmetically sensitive or highly vascular areas. A specialist should weigh diagnostic value against scarring and tissue damage.

There is no universal PMMA antidote

Hyaluronidase breaks down HA, not PMMA. Similarly, saline, massage, heat, unregulated enzymes, and internet “dissolvers” do not reliably remove acrylic microspheres. Consequently, attempts to dissolve PMMA outside medical care may add infection, burns, necrosis, or new foreign material.

The FDA’s 2025 review found no approved reversal agent for PMMA, CaHA, PLLA, or silicone fillers. Moreover, the agency noted that medical-device adverse-event reports cannot establish incidence or causality. Still, the absence of a predictable reversal method remains a central practical difference between PMMA and HA.

One FDA analysis identified 5,945 serious-injury device reports that referenced filler removal, dissolution, or dispersion. Within that search, 5,171 reports included hyaluronidase terms, 742 included excision, and 53 included sodium thiosulfate; reports could include more than one management approach. Importantly, the FDA executive summary covers fillers as a class, reflects uneven voluntary reporting, and cannot reveal procedure-specific incidence. The figures describe postmarket management reports, not proof that any intervention works for PMMA.

Medical treatment targets the suspected cause

Clinicians may use antibiotics for confirmed or strongly suspected infection and anti-inflammatory therapy for selected sterile inflammatory reactions. Some specialists inject corticosteroids or other agents into localized granulomas, while systemic disease may require endocrinology or nephrology management. However, treatment can produce side effects, relapse can occur, and immunosuppression may worsen an unrecognized infection.

Because evidence often comes from case reports and expert practice, multidisciplinary care improves decision-making in severe cases. For example, an ophthalmic vascular event, genital necrosis, hypercalcemia, or extensive gluteal disease requires very different teams and priorities.

Surgery can debulk PMMA but may not erase it

Surgeons may excise a discrete nodule, remove inflamed tissue, drain an abscess, reconstruct a defect, or debulk diffuse material. Nevertheless, microspheres can infiltrate normal planes, so complete removal may cause unacceptable damage. Repeat surgery, scarring, grafts, contour defects, or residual inflammation may follow.

An 11-patient midface complication series found limited improvement after corticosteroids in six treated patients, whereas nine underwent surgical debulking and improved. Yet the original Aesthetic Surgery Journal case series was small, retrospective, uncontrolled, and restricted to patients with established complications. Therefore, it supports individualized surgical evaluation rather than a promise that surgery will cure every case.

PMMA Injection Risks: Myths, Facts, and Surprises

Misleading claims can distort how patients understand PMMA injection risks. The following distinctions explain why a technically true statement may still create a false impression of safety.

Myth 1: “Permanent means one procedure and no future maintenance”

Permanent material can create permanent management needs. Although the cosmetic effect may last, aging, asymmetry, inflammation, or changing preferences can lead to later procedures. Therefore, permanence should count as a long-term commitment, not a convenience feature alone.

Myth 2: “A good result after one year proves lifetime safety”

Published granulomas have appeared 6 to 180 months after facial treatment, and a selected complication cohort recorded a presentation after 27.5 years. Consequently, short follow-up misses part of the biologically relevant period. Long latency does not mean a reaction will occur, but it prevents an early result from proving lifetime safety.

Myth 3: “PMMA caused less necrosis than HA in a study, so it is safer”

That counterintuitive result came from deliberately embolized rabbit-ear arteries followed for seven days. Moreover, the experiment did not include human rescue protocols or delayed permanent-filler complications. Thus, it is an interesting rheology experiment, not a clinical verdict.

Myth 4: “Medical-grade material cannot cause a foreign-body reaction”

Medical-grade manufacturing reduces contamination and variability; it does not make a permanent polymer biologically invisible. In fact, the desired collagen response itself begins with tissue interaction around microspheres. Excessive or dysregulated inflammation can produce nodules or granulomas.

Myth 5: “HA is completely safe because it can be dissolved”

HA can cause the same time-critical vascular emergencies as other fillers. Furthermore, hyaluronidase response varies, and no treatment reliably reverses all cases of filler-related blindness. The practical advantage is greater manageability in many situations, not immunity from harm.

Myth 6: “Published complication counts reveal the true incidence”

A case series answers “What happened to these referred patients?” It does not answer “How often does this happen among everyone treated?” Therefore, the 587-complication review should not become a numerator over an invented denominator, while a small industry trial should not erase rare late harms either.

Myth 7: “A larger dose only creates a larger version of the same facial result”

Scaling from milliliters to hundreds of milliliters changes tissue pressure, exposed surface area, inflammatory burden, number of injection passes, and consequences of contamination. In addition, gluteal anatomy differs fundamentally from a cheek scar. Dose extrapolation without evidence is not a minor variation.

Myth 8: “If removal is possible, PMMA is reversible”

Surgical excision and chemical dissolution are not equivalent. A surgeon may remove a localized lump, but diffuse particles can interweave with healthy tissue. As a result, “removable” may mean debulking through scars with residual material, not restoration of the pre-injection anatomy.

How Sources About PMMA Injection Risks Were Evaluated

Reliable health writing weighs sources about PMMA injection risks rather than counting links. Primary regulatory documents, product labels, systematic reviews, and peer-reviewed clinical studies carry more evidentiary weight than clinic blogs or product sellers.

Supplied reference	Source type	What it contributes	How much weight it should carry
The Aesthetic Guide: PMMA Injection Complications	Trade publication summary	Accessible discussion of an 11-patient midface complication series	Useful context, but the original peer-reviewed case series should support clinical claims.
PMC: rabbit-ear PMMA vs HA embolism study	Peer-reviewed animal experiment	Controlled comparison of acute necrosis after deliberate arterial embolization	Valid for its narrow model; not evidence of overall human or long-term superiority.
Rejuvall penile PMMA case study	Clinic-authored web case	Illustrates a possible severe patient journey and practical concerns	Anecdotal and non-peer-reviewed; cannot establish frequency, causation, or comparative safety.
Dermax PMMA safety page	Manufacturer or seller content	Shows how a commercial source frames product safety and technique	Commercial conflict limits independence; verify every medical claim against regulators and peer-reviewed research.
FDA labeling and safety pages	Regulator and primary product documents	Approved indication, contraindications, study events, warnings, and postmarket context	Highest relevance for US regulatory claims, although reporting systems cannot calculate incidence.
Systematic reviews and clinical series	Peer-reviewed secondary and observational evidence	Patterns, latency, mechanisms, and treatment experience	Valuable but limited by heterogeneity, selection, publication bias, and short or incomplete follow-up.

The deeper search also included the 2024 integrative review of 587 complication reports, the ECRI safety profile prepared for FDA, a 2020 facial-filler systematic review, a hypercalcemia systematic review, a 209-patient complication cohort, FDA product labeling, and current Anvisa statements. Accordingly, the conclusions do not depend on a clinic’s marketing position for or against one product.

Frequently Asked Questions About PMMA Injection Risks

These concise answers address common search questions about PMMA injection risks. However, individual decisions still require a clinician who knows the exact product, site, dose, and medical history.

Is PMMA toxic to the body?

Medical PMMA is a biocompatible polymer, not a poison in the ordinary sense. However, biocompatibility does not mean inert in every person, dose, site, or formulation. The body can form chronic inflammation, fibrosis, nodules, or granulomas around permanent microspheres, while procedural errors can cause vascular and infectious harm.

How common are PMMA injection risks?

No reliable universal percentage exists. Controlled Bellafill studies, facial cohorts, high-volume complication reports, and off-label procedures involve different products and circumstances. Therefore, patients should reject anyone who presents one number as the lifetime risk for every PMMA injection.

Is PMMA cancer-causing?

Current dermal-filler evidence does not establish that approved PMMA microspheres cause cancer. Nevertheless, a new mass should not automatically be labeled a filler reaction. Clinicians may need imaging or biopsy to distinguish granuloma, infection, scar, and unrelated disease.

How long after PMMA can complications appear?

Complications can appear during injection, within days, or many years later. For example, facial granulomas in a systematic review appeared from 6 to 180 months after treatment, while a complication-selected cohort included a case at 330 months. Therefore, patients should retain product records indefinitely.

Can hyaluronidase dissolve PMMA?

No. Hyaluronidase breaks down hyaluronic acid, not acrylic PMMA microspheres. Consequently, a clinic that promises to “melt” PMMA with standard HA dissolver is making a biologically implausible claim.

Can a surgeon remove all PMMA?

Sometimes a surgeon can remove a discrete deposit or debulk affected tissue. However, diffuse particles may integrate with healthy fat, skin, muscle, vessels, or nerves. Complete removal can therefore prove impossible or cause significant scarring and functional damage.

Is a cannula safer than a needle for PMMA?

Cannulas may reduce vascular-occlusion odds for fillers overall in experienced hands, according to retrospective dermatologist data. Still, cannulas can enter vessels, and the study did not establish PMMA-specific safety. Technique, anatomy, product, site, pressure, and volume all remain important.

What is the safest permanent filler?

No permanent filler is universally safest. A permanent implant trades repeat treatment for less reversibility and longer exposure to delayed problems. For an elective first treatment, a temporary option or no filler often deserves discussion before any permanent product.

Are PMMA buttock injections safe in small amounts?

The FDA has approved no filler for buttock augmentation or large-scale body contouring. Although smaller volume may reduce some dose-related hazards, no threshold converts an unapproved gluteal indication into proven safety. Anatomy, sterility, cumulative sessions, product quality, and intravascular risk still matter.

Is PMMA safer when a physician injects it?

Training and legitimate clinical safeguards can reduce preventable errors. Nevertheless, a credential cannot make an unapproved site, excessive dose, counterfeit product, or permanent material reversible. The best clinician should also know when not to inject.

What should I do if I already have PMMA and feel well?

Do not panic or seek preventive removal solely because the material is present. Instead, keep the product and treatment records, tell relevant clinicians about the implant, and watch for new local or systemic symptoms. Routine imaging or blood tests should follow an individualized medical assessment rather than a one-size-fits-all screening schedule.

Which alternative is safer for penile enlargement?

No penile filler has FDA approval, so “safer” does not mean approved or risk-free. A urologist or sexual-medicine specialist can assess anatomy, erectile function, expectations, body-image concerns, traction candidacy, and whether no intervention offers the best balance. Permanent PMMA deserves particular caution because removal can threaten penile skin and function.

Does FDA approval mean a procedure has zero risk?

No. Approval means the agency found adequate evidence of safety and effectiveness for a specific product used as labeled in a defined population. It does not guarantee an individual result, eliminate rare events, or validate off-label body areas and volumes.

Questions to Ask About PMMA Injection Risks

Use this PMMA injection risks checklist and request clear answers before paying a deposit:

1. What exact diagnosis or anatomical issue are we treating?
2. What is the product’s brand, manufacturer, lot number, and regulatory registration?
3. Is this product approved for this exact body area and purpose?
4. How much will you inject per site and in total?
5. Which temporary, surgical, noninvasive, and no-treatment options could meet the same goal?
6. What complications have you personally managed, and what is your emergency protocol?
7. If a vessel becomes blocked, who provides immediate ophthalmology or hospital care?
8. Can this material be dissolved, and what does removal actually involve?
9. What symptoms require emergency care, same-day review, or routine follow-up?
10. Who will care for me if a delayed problem appears years from now?

A trustworthy consultation should tolerate questions and uncertainty. Conversely, pressure tactics, guarantees, hidden product packaging, unusually large volume, and dismissal of long-term follow-up are reasons to leave.

Key Takeaways on PMMA Injection Risks

PMMA injection risks require a lifetime perspective because the microspheres remain in tissue and no predictable injectable antidote removes them. Limited FDA approval for one branded product in nasolabial folds and selected cheek acne scars does not support PMMA use in the nose, lips, buttocks, penis, or general body contouring. Furthermore, controlled small-volume facial studies cannot establish the safety of high-volume or poorly regulated injections.

The evidence supports a broad complication spectrum: expected short-term reactions, vascular occlusion, necrosis, blindness, infection, nodules, granulomas, fibrosis, migration, chronic edema, disfigurement, hypercalcemia, and kidney injury. However, current literature often cannot provide a precise absolute risk because it combines product-specific trials, heterogeneous cohorts, case series, animal experiments, and severe referral cases.

For appropriate facial goals, temporary HA often offers a more manageable alternative because it degrades and can frequently be reduced with off-label hyaluronidase. Still, every filler carries risk, and neither an enzyme nor a cannula guarantees rescue from blindness or necrosis. Therefore, the safest plan combines a justified indication, regulated product, conservative volume, expert anatomy, emergency readiness, permanent records, and the willingness to choose no injection.

References and Further Reading

Regulatory and official sources

1. US Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers).
2. US Food and Drug Administration. Dermal Filler Do’s and Don’ts for Wrinkles, Lips and More.
3. US Food and Drug Administration. FDA-Approved Dermal Fillers.
4. US Food and Drug Administration. Bellafill PMA approval record, P020012/S009.
5. US Food and Drug Administration. Bellafill Patient Labeling.
6. ECRI for FDA CDRH. Polymethyl Methacrylate Safety Profile. April 13, 2021.
7. US Food and Drug Administration. Dermal Filler Risk and Reversal Executive Summary. 2025.
8. Anvisa. Assessment Maintains PMMA for Previously Approved Indications. July 10, 2025.
9. Anvisa. Use Dermal Fillers Only Within Approved Indications. March 12, 2026.

Peer-reviewed evidence

10. Paulucci BP. PMMA Safety for Facial Filling: A Systematic Review. Aesthetic Plastic Surgery. 2020. doi:10.1007/s00266-019-01522-2.
11. Sampaio et al. The Risks of Polymethyl Methacrylate: An Integrative Review of 587 Complication Reports. Revista Brasileira de Cirurgia Plástica. 2024;39(4). doi:10.1055/s-0044-1801343.
12. Cruz et al. Complications of Polymethyl Methacrylate Use in Esthetic Procedures: A Review. Revista Brasileira de Cirurgia Plástica. 2025;40. doi:10.1055/s-0045-1810589.
13. Complications Related to the Use of PMMA on the Face: Analysis of 209 Cases. Revista Brasileira de Cirurgia Plástica. 2024.
14. Alijotas-Reig et al. Hypercalcemia Associated With Cosmetic Injections of Permanent Filling Materials: A Systematic Review. European Journal of Endocrinology. 2018. doi:10.1530/EJE-17-0938.
15. Sales et al. Hypercalcemia and Chronic Renal Disease Due to Cosmetic PMMA Injections: Two Case Reports. Brazilian Journal of Nephrology. doi:10.1590/2175-8239-JBN-2020-0044.
16. Medeiros et al. Midface PMMA Complications: An 11-Patient Case Series. Aesthetic Surgery Journal. 2016. doi:10.1093/asj/sjv195.
17. Chen et al. Risk Comparison of Filler Embolism Between PMMA and Hyaluronic Acid in a Rabbit Model. Aesthetic Plastic Surgery. 2019. doi:10.1007/s00266-019-01320-w.
18. Alam et al. Rates of Vascular Occlusion Associated With Needles Versus Cannulas for Filler Injection. JAMA Dermatology. 2021. doi:10.1001/jamadermatol.2020.5102.
19. Casavantes et al. Nonsurgical Penile Girth Enhancement Using PMMA Microspheres. Journal of Sexual Medicine. 2016. doi:10.1016/j.jsxm.2016.06.008.
20. Penile Sepsis After PMMA Injection. Journal of Emergency Medicine Reports. 2025. doi:10.1016/j.jemrpt.2025.100160.
21. Complications and Management of Penile Enhancement Procedures. Translational Andrology and Urology. 2025.
22. The Use of Hyaluronidase in Aesthetic Practice. 2024.

Professional safety guidance

23. American Society of Plastic Surgeons and partner societies. Gluteal Fat Grafting: A Joint Safety Statement.
24. International Society of Aesthetic Plastic Surgery. Global Survey 2024.

Editorial methodology

This article prioritizes current regulatory documents and original peer-reviewed evidence about PMMA injection risks. It reports denominators when available, distinguishes human data from animal experiments, and labels complication-selected case series so their proportions are not mistaken for population incidence. Moreover, it treats manufacturer, seller, and clinic pages as contextual sources rather than independent proof of safety or harm. Regulatory status and clinical evidence can change; therefore, readers should verify the current product label and local rules before treatment.